<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062516</url>
  </required_header>
  <id_info>
    <org_study_id>HKEC 2007-176 VerifyNow</org_study_id>
    <nct_id>NCT01062516</nct_id>
  </id_info>
  <brief_title>Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin</brief_title>
  <official_title>Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruttonjee Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruttonjee Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators examine the influence of esomeprazole versus famotidine on antiplatelet
      action of clopidogrel associated with aspirin. At least 100 consecutive patients suffering
      from acute coronary syndrome or undergoing coronary artery stent implantation , who received
      aspirin (80 - 160 mg/day) and clopidogrel (300 mg loading dose, followed by 75 mg/day or
      75mg/day for at least 7 consecutive days), are randomised to receive either esomeprazole 20
      mg daily vs famotidine 40 mg daily in a double blinded manner. Clopidogrel effect was tested
      by measuring residual platelet reactivity (RPR) to ADP by VerifyNow P2Y12 assay (Accumetrics
      Inc, San Diego, Calif). At baseline, whole blood will be obtained for RPR at least 12 h after
      clopidogrel loading dose or at least 7 days of maintaince dose. Immediately obtaining the
      baseline blood, patients will be randomized to receive either esomeprazole (20 mg/day) or
      famotidine 40 mg/day for 28 days. Double blinding will be performed by encapsulation of study
      drugs. RPR will be measured again at the 28th day.

      The investigators will compare the % inhibition and the P2Y12 reaction Units (PRU) at the
      28-day treatment period in the 2 groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P2Y12 reaction units</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percent inhibition</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral esomeprazole 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral famotidine 40mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole 20 mg daily</intervention_name>
    <description>oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famotidine 40 mg daily</intervention_name>
    <description>oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients suffering from acute coronary syndrome or undergoing coronary artery stent
             implantation (PCI) , who received aspirin (80 - 160 mg/day) and clopidogrel (300 mg
             loading dose, followed by 75 mg/day), are recruited.

        Exclusion Criteria:

          -  known active peptic ulcer disease or gastrointestinal within 8 wk

          -  known iron deficiency anemia with Hb &lt; 10 gm/dl

          -  mechanical ventilation

          -  active cancer, liver cirrhosis, end-stage renal failure

          -  life expectancy &lt; 1 yr

          -  known allergic to aspirin, clopidogrel, famotidine or esomeprazole

          -  pregnancy, lactation, child-bearing potential in the absence of contraception,

          -  co-prescription of NSAID, corticosteroid, or warfarin

          -  non-oral feeding or impaired GI absorption e.g. vomiting

          -  patient on proton pump inhibitor within 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fook Hong Ng, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruttonjee Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruttonjee Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>October 2, 2010</last_update_submitted>
  <last_update_submitted_qc>October 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Fook Hong Ng</name_title>
    <organization>Ruttonjee Hospital</organization>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>famotidine</keyword>
  <keyword>platelet function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

